- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05367024
Broccoli Effect on Glycated Haemoglobin (HbA1c) (BETA)
June 13, 2025 updated by: Quadram Institute Bioscience
Broccoli Effect on Glycated Haemoglobin (HbA1c) - BETA Study, A Randomised Double-blinded Crossover Study
Broccoli has shown to normalise elevated blood sugars when eaten over long period of time.
Individuals with pre-diabetes have higher than normal blood sugar levels.
In this study, investigators are trying to understand how broccoli, when eaten as a soup, affects blood sugar levels in individuals with pre-diabetes.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The BETA study is a 36-week randomized, double-blind, placebo-controlled, two-arm crossover intervention study conducted at the Quadram Institute Clinical Research Facility (QI CRF), Norwich, UK.
Investigators are seeking adults with pre-diabetes, to determine whether broccoli soups affect glucose metabolism, compared to a similar soup containing courgette.
There are a total of 9 clinical visits (1 screening visit, 4 short visits, and 4 oral glucose tolerance testing visits).
Investigators will assess blood samples for glycated hemoglobin (HbA1c), fasting plasma glucose, insulin, fructosamine, cholesterol and triglycerides.
Investigators will also quantify the metabolites in urine through analytical analysis and determine whether gene expression is altered by the soups through RNA sequencing.
Participants will consume one of two soups (broccoli or courgette) for the first intervention period then after a twelve-week washout phase (soup holiday), participants will crossover and consume the other soup for the second intervention period.
For each intervention period, soups will be consumed three times a week per twelve-week period.
Investigators will ask the participant to complete lifestyle questionnaires regarding their physical activity and dietary pattern.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Norwich, United Kingdom, NR4 7UQ
- Quadram Institute Bioscience
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Individuals with prediabetes (confirmed through screening)
- Aged 18 and older.
- Body Mass Index (BMI) between 18.5 - 35 kg/m2.
- Living within 40 miles from the Norwich Research Park.
Exclusion Criteria:
The participant will not be able to take part if they('re):
- Screening test results indicate they are not suitable to take part in this study such as HbA1c level at screening visit of < 42 mmol/mol (healthy) and > 47 mmol/mol (diabetes) and BMI at screening visit < 18.5 kg/m2 (underweight) and > 35 kg/m2 (extremely obese).
- Have a known allergy to any of the components (broccoli, courgette, milk, lactose, or gluten) of the test soups.
- Have been diagnosed or have a history of blood or clotting disorders such as anaemia or thrombosis.
- Have been treated for heart disease, cancer, or diabetes.
- Are immunocompromised due to medications or viral infection such human immunodeficiency virus (HIV).
- Have low or high blood pressure with hypertension medication (≤90/60, ≥160/100 respectively would be classed as abnormal).
- Have any acute or chronic illnesses that affects the outcome of the study such as a gastrointestinal disorder. This will be assessed on a case by case basis by QI medical advisor.
- Plan to become pregnant during the study duration, pregnant or breastfeeding.
- Frequently take medications that may interfere with sugar metabolism or absorption such as laxatives, steroids, dietary supplements, or anti-inflammatory medications. This will be assessed on a case by case basis by QI medical advisor.
- Drink more than 14 alcohol units/week.
- Smoke socially or on occasion more than 12.5 grams or 20 cigarettes/week
- Vegan or any dietary restrictions that prevent the consumption of study soups or follow a diet programme which requires fasting for multiple days.
- Are a registered blood donor and have donated a large quantity of blood within the last 16 weeks. Registered blood donors should abstain from blood donations for the duration of the study.
- Are unable to give written or verbal informed consent
- Unable to provide GP contact details.
- Are participating in another dietary intervention study nor given blood in another dietary study in the last 3 months.
- Are related to or living with any member of the study team or part of the management/supervisory structure of the Chief Investigator.
- Have symptoms of COVID-19, been asked to self-isolate, or have been diagnosed with COVID-19 in the last 14 days.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Broccoli soup
The soup will be made with a commercially available dried vegetable soup supplemented with broccoli powder.
|
Participants will consume one broccoli soup three times a week for one 12-week intervention period as part of their normal diet.
|
|
Sham Comparator: Courgette soup
The soup will be made with a commercially available dried vegetable soup supplemented with courgette powder.
|
Participants will consume one courgette soup three times a week for one 12-week intervention period as part of their normal diet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in glycated haemoglobin (HbA1c) after broccoli and courgette soup interventions
Time Frame: Week: 0, 12, 24 and 36.
|
Comparison of fasting blood for HbA1c at baseline and after soup interventions
|
Week: 0, 12, 24 and 36.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in postprandial capillary glucose concentration
Time Frame: 3.5 hours
|
Capillary glucose concentration will be measured by finger prick after administration of a glucose challenge using a standardized 75g glucose beverage (GlucosePro).
Measurements will be taken -15, -10, -5, 15, 30, 45, 60, 90, 120, 150, 180, 210 min post glucose beverage at Week: 0, 12, 24 and 36.
|
3.5 hours
|
|
Change in fasting plasma glucose (mmol/l) after broccoli and courgette soup interventions
Time Frame: Week: 0 to12 and 24 to 36.
|
Comparison of fasting plasma glucose between baseline and at 12 weeks and washout (24 weeks) and 36 weeks.
|
Week: 0 to12 and 24 to 36.
|
|
Change in fasting plasma insulin (mmol/L) after broccoli and courgette soup interventions
Time Frame: Week: 0 to12 and 24 to 36.
|
Comparison of fasting plasma insulin between baseline and at 12 weeks and washout (24 weeks) and 36 weeks.
|
Week: 0 to12 and 24 to 36.
|
|
Change in fasting serum fructosamine (µmol/L) after broccoli and courgette soup interventions
Time Frame: Week: 0 to12 and 24 to 36.
|
Comparison of fasting serum fructosamine between baseline and at 12 weeks as well as washout (24 weeks) and 36 weeks.
|
Week: 0 to12 and 24 to 36.
|
|
Change in fasting serum cholesterol (mmol/L) after broccoli and courgette soup interventions
Time Frame: Week: 0 to12 and 24 to 36.
|
Comparison of fasting serum cholesterol between baseline and at 12 weeks as well as washout (24 weeks) and 36 weeks.
|
Week: 0 to12 and 24 to 36.
|
|
Change in fasting serum triglycerides (mmol/L) after broccoli and courgette soup interventions
Time Frame: Week: 0 to12 and 24 to 36.
|
Comparison of fasting serum triglycerides between baseline and at 12 weeks as well as washout (24 weeks) and 36 weeks.
|
Week: 0 to12 and 24 to 36.
|
|
Change in broccoli metabolites (glucosinolates, sulforaphane, and S-methyl cysteine sulfoxide) in 24 hour urine collection
Time Frame: Week: 0, 12, 24, and 36.
|
Quantification of broccoli metabolite excretion into urine metabolites will be measured from 24-hour urine collections using targeted metabolite analysis of glucosinolates, sulforaphane, and S-methyl cysteine sulfoxide.
These metabolites will be used to define relationships between dietary intake, broccoli metabolism and the biological outcomes
|
Week: 0, 12, 24, and 36.
|
|
Treatment effects on whole blood gene expression from RNAseq
Time Frame: up to 36 weeks.
|
The effect of soup consumption will be tested using edgeR and Limma to fit linear models to gene expression data.
False discovery rate will be corrected using the Benjamin Hochberg procedure
|
up to 36 weeks.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Paul A Kroon, PhD, Quadram Institute Bioscience
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 27, 2021
Primary Completion (Estimated)
April 1, 2026
Study Completion (Estimated)
December 1, 2026
Study Registration Dates
First Submitted
October 4, 2021
First Submitted That Met QC Criteria
May 4, 2022
First Posted (Actual)
May 10, 2022
Study Record Updates
Last Update Posted (Actual)
June 15, 2025
Last Update Submitted That Met QC Criteria
June 13, 2025
Last Verified
June 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- QIB06-2020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.